作者
Amrou Sarraj,Michael Abraham,Ameer E Hassan,Spiros Blackburn,Scott E. Kasner,Santiago Ortega‐Gutiérrez,Muhammad Shazam Hussain,Michael Chen,Hannah Johns,Leonid Churilov,Deep Pujara,Faris Shaker,Laith Maali,Père-Joan Cardona,Nabeel Herial,Daniel Gibson,Osman Kozak,Juan F. Arenillas,Bernard Yan,Natàlia Pérez de la Ossa,Sophia Sundararajan,Yin Hu,Dennis Cordato,Nathan Manning,Ricardó A. Hanel,Amin N. Aghaebrahim,Ronald F. Budzik,William J. Hicks,Jordi Blasco,Teddy Y. Wu,Jenny Tsai,Joanna D. Schaafsma,Chirag D. Gandhi,Fawaz Al‐Mufti,Navdeep Sangha,Steven Warach,Timothy Kleinig,Vignan Yogendrakumar,Felix Ng,Edgar A. Samaniego,Mohammad A Abdulrazzak,Mark Parsons,Mohammad H Rahbar,Thanh N. Nguyen,Johanna T Fifi,Vítor Mendes Pereira,Maarten G. Lansberg,Gregory W. Albers,Anthony J. Furlan,Pascal Jabbour,Clark Sitton,Cathy Sila,Nicholas C. Bambakidis,Stephen M. Davis,Lawrence R. Wechsler,Michael D. Hill,James C. Grotta,Marc Ribó,Bruce Campbell
摘要
Summary
Background
Multiple randomised trials have shown efficacy and safety of endovascular thrombectomy in patients with large ischaemic stroke. The aim of this study was to evaluate long-term (ie, at 1 year) evidence of benefit of thrombectomy for these patients. Methods
SELECT2 was a phase 3, open-label, international, randomised controlled trial with blinded endpoint assessment, conducted at 31 hospitals in the USA, Canada, Spain, Switzerland, Australia, and New Zealand. Patients aged 18–85 years with ischaemic stroke due to proximal occlusion of the internal carotid artery or of the first segment of the middle cerebral artery, showing large ischaemic core on non-contrast CT (Alberta Stroke Program Early Computed Tomographic Score of 3–5 [range 0–10, with lower values indicating larger infarctions]) or measuring 50 mL or more on CT perfusion and MRI, were randomly assigned, within 24 h of ischaemic stroke onset, to thrombectomy plus medical care or to medical care alone. The primary outcome for this analysis was the ordinal modified Rankin Scale (range 0–6, with higher scores indicating greater disability) at 1-year follow-up in an intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT03876457) and is completed. Findings
The trial was terminated early for efficacy at the 90-day follow-up after 352 patients had been randomly assigned (178 to thrombectomy and 174 to medical care only) between Oct 11, 2019, and Sept 9, 2022. Thrombectomy significantly improved the 1-year modified Rankin Scale score distribution versus medical care alone (Wilcoxon-Mann-Whitney probability of superiority 0·59 [95% CI 0·53–0·64]; p=0·0019; generalised odds ratio 1·43 [95% CI 1·14–1·78]). At the 1-year follow-up, 77 (45%) of 170 patients receiving thrombectomy had died, compared with 83 (52%) of 159 patients receiving medical care only (1-year mortality relative risk 0·89 [95% CI 0·71–1·11]). Interpretation
In patients with ischaemic stroke due to a proximal occlusion and large core, thrombectomy plus medical care provided a significant functional outcome benefit compared with medical care alone at 1-year follow-up. Funding
Stryker Neurovascular.